Venture Visionary Partners
AXDX icon

Venture Visionary Partners’s Accelerate Diagnostics AXDX Stock Holding History

Venture Visionary Partners’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-25
Closed -$248 – 537
2022
Q2 		$248 Buy
+25
New +$221 ﹤0.01% 1680

Other funds holding AXDX

GAM
Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CIA
Cladis Investment Advisory Billings, Montana $214M AUM 45.87% 1-Year Est. Return

Venture Visionary Partners's AXDX Position: Q3 2022 in Review

Venture Visionary Partners sold out of Accelerate Diagnostics (AXDX) in Q3 2022, closing a stake of 25 shares — an estimated $248 sold.

Venture Visionary Partners first reported a position in AXDX in Q2 2022 and held it in 1 quarter. The position peaked at $248 in Q2 2022. 84 funds tracked by Wall St. Rank hold AXDX as of Q3 2022.

  • Venture Visionary Partners reported no remaining Accelerate Diagnostics position as of Q3 2022 after selling out during the quarter.
  • Venture Visionary Partners sold 25 Accelerate Diagnostics shares in Q3 2022, an estimated $248.
  • Venture Visionary Partners first reported a position in Accelerate Diagnostics in Q2 2022 and held it in 1 quarter.
  • Venture Visionary Partners's Accelerate Diagnostics position peaked at $248 in Q2 2022.
  • 84 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q3 2022.

Based on Venture Visionary Partners's 13F filing for Q3 2022, filed 14 Nov 2022.